-
2
-
-
0034641568
-
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study
-
COI: 1:STN:280:DC%2BD3cvisFWnsg%3D%3D, PID: 10938048
-
Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405–12.
-
(2000)
BMJ.
, vol.321
, pp. 405-412
-
-
Stratton, I.M.1
Adler, A.I.2
Neil, H.A.3
-
3
-
-
84989322701
-
Treatment guide for diabetes 2013-2014
-
Japanese Diabetes Society (ed). Treatment guide for diabetes 2013-2014. Tokyo: Japanese Diabetes Society; 2014.
-
(2014)
Tokyo: Japanese Diabetes Society
-
-
-
5
-
-
84989314435
-
-
Japan Diabetes Clinical Data Management Study Group. Basic data tabulation (2013) [in Japanese] Accessed 15 Dec 2015.
-
Japan Diabetes Clinical Data Management Study Group. Basic data tabulation (2013) [in Japanese]. Available at: http://jddm.jp/study/index.html. Accessed 15 Dec 2015.
-
-
-
-
6
-
-
0035146344
-
Renal gluconeogenesis: its importance in human glucose homeostasis
-
COI: 1:CAS:528:DC%2BD3MXhtlKgsrc%3D, PID: 11213896
-
Gerich JE, Meyer C, Woerle HJ, et al. Renal gluconeogenesis: its importance in human glucose homeostasis. Diabetes Care. 2001;24:382–91.
-
(2001)
Diabetes Care.
, vol.24
, pp. 382-391
-
-
Gerich, J.E.1
Meyer, C.2
Woerle, H.J.3
-
7
-
-
84885171560
-
The clinical efficacy and safety of sodium glucose cotransporter-2 inhibitors in adults with type 2 diabetes mellitus
-
COI: 1:CAS:528:DC%2BC3sXhsVSitLrE, PID: 23744749
-
Riser Taylor S, Harris KB. The clinical efficacy and safety of sodium glucose cotransporter-2 inhibitors in adults with type 2 diabetes mellitus. Pharmacotherapy. 2013;33:984–99.
-
(2013)
Pharmacotherapy
, vol.33
, pp. 984-999
-
-
Riser Taylor, S.1
Harris, K.B.2
-
8
-
-
76249133903
-
Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications
-
COI: 1:CAS:528:DC%2BC3cXjvF2mtLg%3D, PID: 20546255
-
Gerich JE. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med. 2010;27:136–42.
-
(2010)
Diabet Med.
, vol.27
, pp. 136-142
-
-
Gerich, J.E.1
-
9
-
-
57949111356
-
Enhanced expressions of sodium-glucose cotransporters in the kidneys of diabetic Zucker rats
-
COI: 1:CAS:528:DC%2BD1cXhsFChurfO, PID: 19095325
-
Tabatabai NM, Sharma M, Blumenthal SS, et al. Enhanced expressions of sodium-glucose cotransporters in the kidneys of diabetic Zucker rats. Diabetes Res Clin Pract. 2009;83:e27–30.
-
(2009)
Diabetes Res Clin Pract.
, vol.83
, pp. e27-e30
-
-
Tabatabai, N.M.1
Sharma, M.2
Blumenthal, S.S.3
-
10
-
-
79960132085
-
A paradigm shift in diabetes therapy: dapagliflozin and other SGLT2 inhibitors
-
PID: 21447284
-
Chao EC. A paradigm shift in diabetes therapy: dapagliflozin and other SGLT2 inhibitors. Discov Med. 2011;11:255–63.
-
(2011)
Discov Med.
, vol.11
, pp. 255-263
-
-
Chao, E.C.1
-
11
-
-
0021813187
-
Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man
-
COI: 1:CAS:528:DyaL2MXlslKnu7k%3D, PID: 3899825
-
Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–9.
-
(1985)
Diabetologia.
, vol.28
, pp. 412-419
-
-
Matthews, D.R.1
Hosker, J.P.2
Rudenski, A.S.3
-
12
-
-
84914181817
-
Efficacy and safety of dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise
-
COI: 1:CAS:528:DC%2BC2cXhslemtrfF, PID: 24909293
-
Kaku K, Kiyosue A, Inoue S, et al. Efficacy and safety of dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise. Diabetes Obes Metab. 2014;16:1102–10.
-
(2014)
Diabetes Obes Metab.
, vol.16
, pp. 1102-1110
-
-
Kaku, K.1
Kiyosue, A.2
Inoue, S.3
-
13
-
-
84915738768
-
Dapagliflozin as monotherapy or combination therapy in Japanese patients with type 2 diabetes: an open-label study
-
COI: 1:CAS:528:DC%2BC2cXhvVGisLrN, PID: 25341477
-
Kaku K, Maegawa H, Tanizawa Y, et al. Dapagliflozin as monotherapy or combination therapy in Japanese patients with type 2 diabetes: an open-label study. Diabetes Ther. 2014;5:415–33.
-
(2014)
Diabetes Ther.
, vol.5
, pp. 415-433
-
-
Kaku, K.1
Maegawa, H.2
Tanizawa, Y.3
-
14
-
-
84891526739
-
Impact of sodium glucose cotransporter 2 inhibitors on weight in patients with type 2 diabetes mellitus
-
PID: 24113667
-
Barnett AH. Impact of sodium glucose cotransporter 2 inhibitors on weight in patients with type 2 diabetes mellitus. Postgrad Med. 2013;125:92–100.
-
(2013)
Postgrad Med.
, vol.125
, pp. 92-100
-
-
Barnett, A.H.1
-
15
-
-
84962339296
-
Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition
-
COI: 1:CAS:528:DC%2BC28XnsFGlsrk%3D, PID: 26078479
-
Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015;38:1687–93.
-
(2015)
Diabetes Care.
, vol.38
, pp. 1687-1693
-
-
Peters, A.L.1
Buschur, E.O.2
Buse, J.B.3
Cohan, P.4
Diner, J.C.5
Hirsch, I.B.6
-
16
-
-
84858020943
-
Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin
-
COI: 1:CAS:528:DC%2BC38Xkt1yms78%3D, PID: 22238392
-
Bolinder J, Ljunggren Ö, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012;97:1020–31.
-
(2012)
J Clin Endocrinol Metab
, vol.97
, pp. 1020-1031
-
-
Bolinder, J.1
Ljunggren, Ö.2
Kullberg, J.3
-
17
-
-
84930087193
-
A reduction in both visceral and subcutaneous fats contributes to increased adiponectin by lifestyle intervention in the Diabetes Prevention Program
-
COI: 1:CAS:528:DC%2BC2cXhs1Kgt7fI, PID: 25267081
-
Zhang C, Luo H, Gao F, et al. A reduction in both visceral and subcutaneous fats contributes to increased adiponectin by lifestyle intervention in the Diabetes Prevention Program. Acta Diabetol. 2015;52(3):625–8.
-
(2015)
Acta Diabetol.
, vol.52
, Issue.3
, pp. 625-628
-
-
Zhang, C.1
Luo, H.2
Gao, F.3
-
18
-
-
84916603703
-
Effects of a community-based weight loss intervention on adipose tissue circulating factors
-
PID: 25293442
-
Miller GD, Isom S, Morgan TM, et al. Effects of a community-based weight loss intervention on adipose tissue circulating factors. Diabetes Metab Syndr. 2014;8:205–11.
-
(2014)
Diabetes Metab Syndr.
, vol.8
, pp. 205-211
-
-
Miller, G.D.1
Isom, S.2
Morgan, T.M.3
-
19
-
-
84893827104
-
Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
-
COI: 1:CAS:528:DC%2BC2cXis1ersL0%3D, PID: 24463448
-
Merovci A, Solis-Herrera C, Daniele G, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest. 2014;124:509–14.
-
(2014)
J Clin Invest.
, vol.124
, pp. 509-514
-
-
Merovci, A.1
Solis-Herrera, C.2
Daniele, G.3
-
20
-
-
84893872877
-
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
-
COI: 1:CAS:528:DC%2BC2cXis1ers7c%3D, PID: 24463454
-
Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014;124:499–508.
-
(2014)
J Clin Invest.
, vol.124
, pp. 499-508
-
-
Ferrannini, E.1
Muscelli, E.2
Frascerra, S.3
-
21
-
-
84937763347
-
Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion
-
COI: 1:CAS:528:DC%2BC2MXnvFSqurY%3D, PID: 25894829
-
Bonner C, Kerr-Conte J, Gmyr V, Queniat G, Moerman E, Thévenet J, et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med. 2015;21(5):512–7.
-
(2015)
Nat Med.
, vol.21
, Issue.5
, pp. 512-517
-
-
Bonner, C.1
Kerr-Conte, J.2
Gmyr, V.3
Queniat, G.4
Moerman, E.5
Thévenet, J.6
-
22
-
-
84889670998
-
Role of KATP channels in glucose-regulated glucagon secretion and impaired counterregulation in type 2 diabetes
-
COI: 1:CAS:528:DC%2BC3sXhvFOksL3O, PID: 24315372
-
Zhang Q, Ramracheya R, Lahmann C, Tarasov A, Bengtsson M, Braha O, et al. Role of KATP channels in glucose-regulated glucagon secretion and impaired counterregulation in type 2 diabetes. Cell Metab. 2013;18(6):871–82.
-
(2013)
Cell Metab.
, vol.18
, Issue.6
, pp. 871-882
-
-
Zhang, Q.1
Ramracheya, R.2
Lahmann, C.3
Tarasov, A.4
Bengtsson, M.5
Braha, O.6
-
23
-
-
84887147788
-
Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study
-
COI: 1:CAS:528:DC%2BC3sXhslCrs7%2FO, PID: 23782594
-
Inagaki N, Kondo K, Yoshinari T, et al. Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study. Diabetes Obes Metab. 2013;15:1136–45.
-
(2013)
Diabetes Obes Metab.
, vol.15
, pp. 1136-1145
-
-
Inagaki, N.1
Kondo, K.2
Yoshinari, T.3
-
24
-
-
84872166360
-
Suppression of oxidative stress by β-hydroxybutyrate, an endogenous histone deacetylase inhibitor
-
COI: 1:CAS:528:DC%2BC3sXjvVCnsA%3D%3D, PID: 23223453
-
Shimazu T, Hirschey MD, Newman J, et al. Suppression of oxidative stress by β-hydroxybutyrate, an endogenous histone deacetylase inhibitor. Science. 2013;339:211–4.
-
(2013)
Science.
, vol.339
, pp. 211-214
-
-
Shimazu, T.1
Hirschey, M.D.2
Newman, J.3
|